Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | APEX1 | P27695 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | CCR2 | P41597 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4303557 | 0.81 | NTRK1 (0.41) | — | |
| SCHEMBL4308707 | 0.80 | CCR9 (0.54) | CCR2 | |
| SCHEMBL13912926 | 0.79 | ATM (0.48) | MEN1KMT2AKDM4E | |
| SCHEMBL6279039 | 0.78 | L3MBTL1 (0.59) | L3MBTL1APEX1MEN1KMT2AKDM4E | |
| SCHEMBL4307241 | 0.77 | L3MBTL1 (0.55) | L3MBTL1APEX1MEN1KMT2AKDM4E | |
| SCHEMBL4308750 | 0.77 | L3MBTL1 (0.66) | L3MBTL1APEX1MEN1KMT2AKDM4E | |
| SCHEMBL3067363 | 0.75 | L3MBTL1 (0.64) | L3MBTL1APEX1MEN1KMT2AKDM4E | |
| SCHEMBL18180193 | 0.74 | APEX1 (0.77) | APEX1MEN1KMT2AKDM4EGLA | |
| SCHEMBL7463101 | 0.73 | CCR2 (0.71) | L3MBTL1APEX1MEN1KMT2AKDM4E | |
| SCHEMBL15828557 | 0.73 | DAO (0.59) | MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062280-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | MERCK SHARP & DOHME CORP. | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062280-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | KCNN3, KCNN1, KCNN2 | L3MBTL1 4741/4885APEX1 3671/4885MEN1 984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.